TEST:

Signatera™

Are you using ctDNA MRD assays like Signatera for your patients with early stage #breastcancer ? But Medicare is covering Signatra. I have NO conflict 😀 (@jamecancerdoc)

What type of ctDNA assays do you like to use here? Is there a Signatera-like/tissue-informed choice in #urothelialcarcinoma, or just a general cell-free DNA approach? #TumorBoardTuesday I imagine this could also be really interesting when treating FGFR fusions w targeted agents. (@JohnEbbenMDPhD)

Great story highlighting the potential of liquid biopsy to detect #colorectalcancer recurrence in patients with early stage disease using Signatera from @NateraGenetics. @skopetz killing it as usual. (@jonmizrahi)

$NTRA New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma https://t.co/MJ9IxREVsU (@stock_titan)

Join me and @HKennecke as we break down the latest Signatera #ctdna data in GI malignancies with real world examples straight from the clinic. 🧬🧬 (@OncoJurdi)

Wonderful poster walk session @alantanmd #GU23 featuring work with ctDNA and Signatera ! Much more to come! We learned so much! @ASCO ()

Signatera data from @arnabguonc, @alantanmd and @LDyrskjot was featured in the #MIBC and #RCC poster walks at #ASCOGU23. Productive #GU23 meeting for #TeamNatera! @OlgaAlexeeva16 @BlkBoiScientist @MarkCalhoun_ @CarciaCarson @npajakMSL @ShrutiS97567202 ()

How can #Signatera #ctDNA help treatment decisions in #RCC? Watch @arnabguonc answer @CParkMD's questions about new data from #ASCOGU23 #GU23 ()

Does #KidneyCancer shed detectable #ctDNA? Watch @tompowles1 interview @arnabguonc on his 45 patient poster with @alantanmd in #mRCC #Signatera #ASCOGU23 #GU23 ()

What an honor to have Dr. @tompowles1 come by and review our Signatera poster with @PBarataMD and hardworking folks at @NateraGenetics at @ASCO #GU23! Big fan of @Uromigos! @CParkMD @brian_rini @JasonBrownMDPhD @koshkin85 @AmandaNizamMD @TulaneDDoM ()

Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer https://t.co/pCTV0IMTuA ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

Signatera #ctDNA in Anal Cancer presented by Dr Janet Alvarez of @MSKCancerCenter. Early and reliable response assessment. 100 days on average before traditional restaging methods. @JoshSmithMDPhD ()

#ctDNA kinetics using @NateraOncology Signatera on St I-III #crcsm (60% had 1st draw 0-12 wks postop). Higher cfDNA conc in 2-4 wks and highest ctDNA+ in 1st 2 wks but cfDNA does not impact ctDNA detection. Could send for ctDNA as soon as 2 wks post-op? #GI23 @OncoAlert ()

CIRCULATE-Japan @NatureMedicine, seeking MRD (Signatera @NateraOncology ) guided optimal adjuvant treatment in CRC patients. Looking forward to checking more data on thoracic malignancies especially NSCLC with or without EGFR mutation. https://t.co/j5PRM6gjWb ()

1b Er/Pr+ #breastcancer w/+ #ctDNA #MRD via #signatera. Tagging ppl assoc w/these #’s to share my experience @JAMAOnc @hthrparsons @FilippoMontemu1 @CarlosHBarcenas @stolaney1 @ArielleMedford @nlinmd @aaleshin @NCIDirector @maryam_lustberg @Dr_RShatsky @DanaFarber @HillStirSci ()

🔥ctDNA to predict risk of recurrence in esophagogastric cancer 🔥 @JCOPO_ASCO https://t.co/NmGrUjVE2n ✅🇺🇸RWD 295pts 🔎Signatera/16 pt specific SNVs -> ctDNA pos.: 👉pre-OP: 96% 👉post-OP: 23% -> strongly associated with RFS 👏Helpful for risk stratification @myESMO @OncoAlert ()

@skopetz hello sir I’m stage 4 colon cancer chemo didn’t work I have the braf v600e mutation I started keytruda 3 months ago and just got my signatera results back and they are now negative do you recommend I be taking anything else with this. Thanks ()

I just finished treatment for stage 1 HR+ breast cancer.Did great w/all treatments & all scans clear.Did #signatera testing to monitor for recurrence, thinking I would get a head start on treatment in event of recurrence.First test positive (!) but there is no approved treatment! ()

Personalized, ctDNA analysis to detect minimal residual disease & identify Pts at high risk of relapse w/ multiple myeloma - @bhemato et al. @Phari #ASCO21 Abstract 8029 https://t.co/OyywlExqea #mmsm #mmMRD n=28 BM flow vs @NateraOncology Signatera MRD @ 3 months post-AHCT ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS : ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS: https://t.co/cP0ckth4U0 ()

Medicare extended coverage of @NateraOncology Signatera™ minimal residual disease (MRD) #ctDNA test to Muscle-Invasive #bladdercancer on July 18, 22 @oncolaert @practiceupdate @BladderCancerUS @tompowles1 @MattGalsky; I will use test to select patients for adjuvant therapy in: ()